The White House reports a 3.1% drop in prescription drug prices over the past year, the steepest decline since 1963, attributing it to President Trump's Most Favored Nation policies and TrumpRx discounts. Drugmakers like Pfizer have agreed to significant price cuts on several medications.
The IRA's price controls could raise long-term drug prices by 21% for the first 25 selected drugs, while Medicare's $2,000 out-of-pocket cap encourages plans to favor IV over equally effective subcutaneous versions.
Xolair may be dropped from Medicare price negotiations as a biosimilar launch looms. The CMS must decide if the biosimilar is a true competitor. The outcome could set precedent for future biosimilar-facing selections.
Trump’s Most Favoured Nation drug pricing plan would tie some U.S. drug prices to lower foreign prices. The source articles say the policy could delay launches in Canada, raise Canadian prices and affect R&D decisions.
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
US health policy activity this week included HHS FY 2027 budget hearings, a House review of Medicare fraud and bipartisan discussion of PBM reform. President Trump also issued an executive order on mental illness treatments, and CMS and FDA announced the RAPID pathway.
Q1 2026 sleep medicine trends include broader use of AI, expanding obstructive sleep apnea and narcolepsy treatments, and policy changes affecting reimbursement and access.
Precision medicine is transforming healthcare through genetic testing and AI integration, with research showing direct-to-consumer testing identifies unknown health risks and drives medical action. However, reimbursement systems lag behind scientific advances, creating barriers to widespread adoption of personalized treatment approaches.
Sixteen pharmaceutical companies have voluntarily agreed to Most Favored Nation pricing covering 70% of Medicare drug spending, while industry leaders warn of China's growing competitiveness in drug development and clinical trials.
New initiatives aim to address social determinants of health in oncology, while research reveals persistent disparities in treatment access and clinical trial participation for Black and minority cancer patients.
